Geode Capital Management’s Champions Oncology CSBR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$444K Buy
77,177
+1,358
+2% +$8.63K ﹤0.01% 3630
2025
Q4
$524K Buy
75,819
+1,410
+2% +$9.39K ﹤0.01% 3568
2025
Q3
$482K Sell
74,409
-776
-1% -$5.47K ﹤0.01% 3629
2025
Q2
$554K Buy
75,185
+51
+0.1% +$360 ﹤0.01% 3524
2025
Q1
$652K Buy
75,134
+8,623
+13% +$87.4K ﹤0.01% 3444
2024
Q4
$570K Buy
66,511
+1,447
+2% +$7.28K ﹤0.01% 3560
2024
Q3
$317K Buy
65,064
+1,978
+3% +$9.28K ﹤0.01% 3746
2024
Q2
$326K Buy
63,086
+972
+2% +$4.74K ﹤0.01% 3733
2024
Q1
$304K Buy
62,114
+765
+1% +$4.48K ﹤0.01% 3793
2023
Q4
$332K Hold
61,349
﹤0.01% 3757
2023
Q3
$382K Buy
61,349
+2,433
+4% +$15.4K ﹤0.01% 3705
2023
Q2
$371K Buy
58,916
+8,464
+17% +$43.7K ﹤0.01% 3756
2023
Q1
$203K Buy
50,452
+2
+0% +$9 ﹤0.01% 4044
2022
Q4
$227K Buy
50,450
+2,812
+6% +$18.4K ﹤0.01% 4028
2022
Q3
$357K Hold
47,638
﹤0.01% 3905
2022
Q2
$385K Hold
47,638
﹤0.01% 3903
2022
Q1
$387K Hold
47,638
﹤0.01% 4072
2021
Q4
$381K Hold
47,638
﹤0.01% 4179
2021
Q3
$486K Buy
47,638
+4,685
+11% +$47.7K ﹤0.01% 4038
2021
Q2
$441K Sell
42,953
-49,865
-54% -$506K ﹤0.01% 4000
2021
Q1
$1.05M Buy
92,818
+641
+0.7% +$7.44K ﹤0.01% 3539
2020
Q4
$994K Buy
92,177
+393
+0.4% +$4.05K ﹤0.01% 3376
2020
Q3
$849K Sell
91,784
-220
-0.2% -$1.96K ﹤0.01% 3267
2020
Q2
$879K Buy
92,004
+48,269
+110% +$411K ﹤0.01% 3181
2020
Q1
$323K Buy
43,735
+204
+0.5% +$1.43K ﹤0.01% 3406
2019
Q4
$362K Buy
43,531
+396
+0.9% +$2.44K ﹤0.01% 3609
2019
Q3
$243K Hold
43,135
﹤0.01% 3704
2019
Q2
$337K Hold
43,135
﹤0.01% 3603
2019
Q1
$422K Buy
43,135
+2,816
+7% +$28.1K ﹤0.01% 3498
2018
Q4
$314K Buy
40,319
+16,025
+66% +$184K ﹤0.01% 3541
2018
Q3
$424K Buy
+24,294
New +$216K ﹤0.01% 3525

Other funds holding CSBR

Geode Capital Management's CSBR Position: Q1 2026 in Review

Geode Capital Management increased its Champions Oncology (CSBR) stake by 1.8% in Q1 2026, buying an estimated $8.63K and bringing the position to 77,177 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #3630.

Geode Capital Management first reported a position in CSBR in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.05M in Q1 2021. 25 funds tracked by Wall St. Rank hold CSBR as of Q1 2026.

  • Geode Capital Management held 77,177 shares of Champions Oncology worth $444K as of Q1 2026.
  • Geode Capital Management bought 1,358 Champions Oncology shares in Q1 2026, an estimated $8.63K.
  • Champions Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3630 holding.
  • Geode Capital Management first reported a position in Champions Oncology in Q3 2018 and has held it in 31 quarters since.
  • Geode Capital Management's Champions Oncology position peaked at $1.05M in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.